A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...
Shares of AstraZeneca PLC AZN advanced 1.46% to £102.92 Thursday, on what proved to be an all-around positive trading session ...
While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...
The company has opened its Qualified Institutions Placement (QIP) issue on November 13. The floor price has been fixed at Rs ...
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...
AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Senior Independent Non-Executive Director, Philip Broadley, has made a notable ...
The FTSE 100 index is seen opening eight points higher at 8034, having fallen 1.2% to a three-month low in yesterday’s ...
Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating yesterday. Andrew Berens gave his rating based on several factors, including AstraZeneca’s ...
Investor's Business Daily on MSN2d
AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter BeatAstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback